Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
BeiGene Ltd ( (HK:6160) ) just unveiled an announcement.
BeiGene Ltd has announced a sublease agreement with ChemoCentryx, a subsidiary of Amgen, for office and research space in San Carlos, California. This sublease, valued at approximately $9.9 million, is considered a connected transaction under Hong Kong’s Listing Rules, reflecting BeiGene’s strategic expansion and utilization of internal resources to enhance its research capabilities.
More about BeiGene Ltd
BeiGene Ltd is a biotechnology company that focuses on developing and commercializing innovative molecularly targeted and immuno-oncology drug candidates for cancer treatment. The company operates in the life sciences sector and is known for its commitment to improving patient outcomes through research and development.
YTD Price Performance: 13.46%
Average Trading Volume: 1,813,205
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$179.7B
Find detailed analytics on 6160 stock on TipRanks’ Stock Analysis page.
